Königsson, Kristian
- Department of Clinical Sciences, Swedish University of Agricultural Sciences
Research article2003Peer reviewedOpen access
Konigsson K, Torneke K, Engeland IV, Odensvik K, Kindahl H
The pharmacokinetics and the prostaglandin (PG) synthesis inhibiting effect of flunixin were determined in 6 Norwegian dairy goats. The dose was 2.2 mg/kg body weight administered by intravenous (i.v.), intramuscular (i.m.) and oral (p.o.) routes using a cross-over design. Plasma flunixin content was analysed by use of liquid chromatography and the PG synthesis was evaluated by measuring plasma 15-ketodihydro-PGF(2alpha) by a radioimmuno-assay. Results are presented as median (range). The elimination half-lives (t(1/2.lambda)) were 3.6 (2.0-5.0), 3.4 (2.6-6.8) and 4.3 (3.4-6.1) h for i.v., i.m. and p.o. administration, respectively. Volume of distribution at steady state (Vd(ss)) was 0.35 (0.23-0.41) L/kg and clearance (CL), 110 (60-160) mL/h/kg. The plasma concentrations after oral administration showed a double-peak phenomenon with the two peaks occurring at 0.37 (0.251) and 3.5 (2.5-5.0) h, respectively. Both peaks were in the same order of magnitude. Bioavailability was 79 (53-112) and 58 (35%-120)% for i.m. and p.o. administration, respectively. 15-Ketodihydro-PGF(2alpha). plasma concentrations decreased after flunixin administration independent of the route of administration
Acta Veterinaria Scandinavica
2003, volume: 44, number: 3-4, pages: 153-159
Publisher: DANSKE DYRLAEGEFORENING
https://res.slu.se/id/publ/7604